Literature DB >> 21836136

Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease.

Armand Mekontso Dessap1, Jean-François Deux, Nour Abidi, Cécile Lavenu-Bombled, Giovanna Melica, Bertrand Renaud, Bertrand Godeau, Serge Adnot, Laurent Brochard, Christian Brun-Buisson, Frederic Galacteros, Alain Rahmouni, Anoosha Habibi, Bernard Maitre.   

Abstract

RATIONALE: The pathophysiology of acute chest syndrome (ACS) in patients with sickle cell disease is complex, and pulmonary artery thrombosis (PT) may contribute to this complication.
OBJECTIVES: To evaluate the prevalence of PT during ACS using multidetector computed tomography (MDCT).
METHODS: We screened 125 consecutive patients during 144 ACS episodes. One hundred twenty-one MDCTs (in 103 consecutive patients) were included in the study.
MEASUREMENTS AND MAIN RESULTS: Twenty MDCTs were positive for PT, determining a prevalence of 17% (95% confidence interval, 10-23%). Revised Geneva clinical probability score was similar between patients with PT and those without. D-dimer testing was very often positive (95%) during ACS. A precipitating factor for ACS was less frequently found in patients with PT as compared with those without. Patients with PT exhibited significantly higher platelet counts (517 [273-729] vs. 307 [228-412] 10(9)/L, P < 0.01) and lower bilirubin (28 [19-43] vs. 44 [31-71] μmol/L, P < 0.01) levels at the onset of ACS as compared with others. In addition, patients with PT had a higher platelet count peak (537 [345-785] vs. 417 [330-555] 10(9)/L, P = 0.048) and smaller bilirubin peak (36 [18-51] vs. 46 [32-83] μmol/L, P = 0.048)and lactate dehydrogenase peak (357 [320-704] vs. 604 [442-788] IU/L, P = 0.01) during hospital stay as compared with others.
CONCLUSIONS: PT is not a rare event in the context of ACS and seems more likely in patients with higher platelet counts and lower hemolytic rate during ACS. Patients with sickle cell disease presenting with respiratory symptoms suggestive of ACS may benefit from evaluation for PT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21836136     DOI: 10.1164/rccm.201105-0783OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  Prospective study of sickle cell trait and venous thromboembolism incidence.

Authors:  A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

2.  Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.

Authors:  Enrico M Novelli; Gregory J Kato; Mariana E Hildesheim; Suchitra Barge; Michael P Meyer; Jay Lozier; Andrea Cortese Hassett; Margaret V Ragni; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 3.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 4.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Pulmonary CTA in sickle cell patients: quantitative assessment of enhancement quality.

Authors:  Jeff Jensen; Tony Lin; Elliot K Fishman; Pamela T Johnson
Journal:  Emerg Radiol       Date:  2017-08-11

Review 6.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 7.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

8.  Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.

Authors:  B N Yamaja Setty; Nigel S Key; A Koneti Rao; Suhita Gayen-Betal; Suba Krishnan; Carlton D Dampier; Marie J Stuart
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

9.  Ten tips for managing critically ill patients with sickle cell disease.

Authors:  Armand Mekontso Dessap; M Fartoukh; R F Machado
Journal:  Intensive Care Med       Date:  2016-08-04       Impact factor: 17.440

10.  Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli.

Authors:  Margaret F Bennewitz; Maritza A Jimenez; Ravi Vats; Egemen Tutuncuoglu; Jude Jonassaint; Gregory J Kato; Mark T Gladwin; Prithu Sundd
Journal:  JCI Insight       Date:  2017-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.